FAQ on InMed Pharmaceuticals' INM-089 and Its Potential in Treating AMD

What is INM-089 and who is developing it?

INM-089 is a pharmaceutical drug candidate developed by InMed Pharmaceuticals (NASDAQ: INM), aimed at treating age-related macular degeneration (AMD).

Why is INM-089 significant in the treatment of AMD?

INM-089 has shown promise in preclinical studies for its potential to provide neuroprotection of photoreceptors, preserve retinal function, and improve the integrity of the retinal pigment epithelium, addressing key aspects of AMD.

What are the two forms of AMD mentioned?

The two forms of AMD are dry AMD, which is more common and less severe, and wet AMD, which is rarer but more severe.

How does INM-089 work in treating AMD?

INM-089 works by providing neuroprotection of photoreceptors, improving photoreceptor function, preserving retinal function, improving the integrity of the retinal pigment epithelium, and enhancing the thickness of the outer nuclear layer of the retina.

Where can I find more information about InMed Pharmaceuticals and INM-089?

More information can be found on InMed Pharmaceuticals’ website at www.InMedPharma.com and in the company’s newsroom at https://ibn.fm/INM.

What makes InMed Pharmaceuticals unique in the pharmaceutical industry?

InMed Pharmaceuticals is a global leader in the manufacturing, development, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, with unparalleled cannabinoid manufacturing capabilities.

Who is primarily affected by AMD?

AMD primarily affects older adults, especially those aged 50 and older, leading to vision loss in the central part of the retina.

What are the potential benefits of INM-089 for AMD patients?

Potential benefits include slowing the progression of vision loss, preserving retinal function, and improving the health of the retina’s outer layers, which are crucial for maintaining vision.